205 related articles for article (PubMed ID: 34877810)
1. AXL targeting by a specific small molecule or monoclonal antibody inhibits renal cell carcinoma progression in an orthotopic mice model.
Chen TJ; Mydel P; Benedyk-Machaczka M; Kamińska M; Kalucka U; Blø M; Furriol J; Gausdal G; Lorens J; Osman T; Marti HP
Physiol Rep; 2021 Dec; 9(23):e15140. PubMed ID: 34877810
[TBL] [Abstract][Full Text] [Related]
2. A Functional Role of GAS6/TAM in Nonalcoholic Steatohepatitis Progression Implicates AXL as Therapeutic Target.
Tutusaus A; de Gregorio E; Cucarull B; Cristóbal H; Aresté C; Graupera I; Coll M; Colell A; Gausdal G; Lorens JB; García de Frutos P; Morales A; Marí M
Cell Mol Gastroenterol Hepatol; 2020; 9(3):349-368. PubMed ID: 31689560
[TBL] [Abstract][Full Text] [Related]
3. LncRNA HOTAIR regulates HIF-1α/AXL signaling through inhibition of miR-217 in renal cell carcinoma.
Hong Q; Li O; Zheng W; Xiao WZ; Zhang L; Wu D; Cai GY; He JC; Chen XM
Cell Death Dis; 2017 May; 8(5):e2772. PubMed ID: 28492542
[TBL] [Abstract][Full Text] [Related]
4. Small molecule inhibition of Axl receptor tyrosine kinase potently suppresses multiple malignant properties of glioma cells.
Vouri M; An Q; Birt M; Pilkington GJ; Hafizi S
Oncotarget; 2015 Jun; 6(18):16183-97. PubMed ID: 25980499
[TBL] [Abstract][Full Text] [Related]
5. Axl receptor tyrosine kinase is a potential therapeutic target in renal cell carcinoma.
Yu H; Liu R; Ma B; Li X; Yen HY; Zhou Y; Krasnoperov V; Xia Z; Zhang X; Bove AM; Buscarini M; Parekh D; Gill IS; Liao Q; Tretiakova M; Quinn D; Zhao J; Gill PS
Br J Cancer; 2015 Aug; 113(4):616-25. PubMed ID: 26180925
[TBL] [Abstract][Full Text] [Related]
6. Axl Inhibitor R428 Enhances TRAIL-Mediated Apoptosis Through Downregulation of c-FLIP and Survivin Expression in Renal Carcinoma.
Woo SM; Min KJ; Seo SU; Kim S; Kubatka P; Park JW; Kwon TK
Int J Mol Sci; 2019 Jul; 20(13):. PubMed ID: 31269715
[TBL] [Abstract][Full Text] [Related]
7. AXL targeting reduces fibrosis development in experimental unilateral ureteral obstruction.
Landolt L; Furriol J; Babickova J; Ahmed L; Eikrem Ø; Skogstrand T; Scherer A; Suliman S; Leh S; Lorens JB; Gausdal G; Marti HP; Osman T
Physiol Rep; 2019 May; 7(10):e14091. PubMed ID: 31134766
[TBL] [Abstract][Full Text] [Related]
8. Bemcentinib and Gilteritinib Inhibit Cell Growth and Impair the Endo-Lysosomal and Autophagy Systems in an AXL-Independent Manner.
Zdżalik-Bielecka D; Kozik K; Poświata A; Jastrzębski K; Jakubik M; Miączyńska M
Mol Cancer Res; 2022 Mar; 20(3):446-455. PubMed ID: 34782372
[TBL] [Abstract][Full Text] [Related]
9. Targeting MET and AXL overcomes resistance to sunitinib therapy in renal cell carcinoma.
Zhou L; Liu XD; Sun M; Zhang X; German P; Bai S; Ding Z; Tannir N; Wood CG; Matin SF; Karam JA; Tamboli P; Sircar K; Rao P; Rankin EB; Laird DA; Hoang AG; Walker CL; Giaccia AJ; Jonasch E
Oncogene; 2016 May; 35(21):2687-97. PubMed ID: 26364599
[TBL] [Abstract][Full Text] [Related]
10. Axl-inhibitor bemcentinib alleviates mitochondrial dysfunction in the unilateral ureter obstruction murine model.
Hoel A; Osman T; Hoel F; Elsaid H; Chen T; Landolt L; Babickova J; Tronstad KJ; Lorens JB; Gausdal G; Marti HP; Furriol J
J Cell Mol Med; 2021 Aug; 25(15):7407-7417. PubMed ID: 34219376
[TBL] [Abstract][Full Text] [Related]
11. Implication of the Receptor Tyrosine Kinase AXL in Head and Neck Cancer Progression.
von Mässenhausen A; Brägelmann J; Billig H; Thewes B; Queisser A; Vogel W; Kristiansen G; Schröck A; Bootz F; Brossart P; Kirfel J; Perner S
Int J Mol Sci; 2016 Dec; 18(1):. PubMed ID: 28025482
[TBL] [Abstract][Full Text] [Related]
12. Activation of the Receptor Tyrosine Kinase AXL Regulates the Immune Microenvironment in Glioblastoma.
Sadahiro H; Kang KD; Gibson JT; Minata M; Yu H; Shi J; Chhipa R; Chen Z; Lu S; Simoni Y; Furuta T; Sabit H; Zhang S; Bastola S; Yamaguchi S; Alsheikh H; Komarova S; Wang J; Kim SH; Hambardzumyan D; Lu X; Newell EW; DasGupta B; Nakada M; Lee LJ; Nabors B; Norian LA; Nakano I
Cancer Res; 2018 Jun; 78(11):3002-3013. PubMed ID: 29531161
[TBL] [Abstract][Full Text] [Related]
13. S100A10 Is a Critical Mediator of GAS6/AXL-Induced Angiogenesis in Renal Cell Carcinoma.
Xiao Y; Zhao H; Tian L; Nolley R; Diep AN; Ernst A; Fuh KC; Miao YR; von Eyben R; Leppert JT; Brooks JD; Peehl DM; Giaccia AJ; Rankin EB
Cancer Res; 2019 Nov; 79(22):5758-5768. PubMed ID: 31585940
[TBL] [Abstract][Full Text] [Related]
14. Differential expression of Axl and Gas6 in renal cell carcinoma reflecting tumor advancement and survival.
Gustafsson A; Martuszewska D; Johansson M; Ekman C; Hafizi S; Ljungberg B; Dahlbäck B
Clin Cancer Res; 2009 Jul; 15(14):4742-9. PubMed ID: 19567592
[TBL] [Abstract][Full Text] [Related]
15. R428, a selective small molecule inhibitor of Axl kinase, blocks tumor spread and prolongs survival in models of metastatic breast cancer.
Holland SJ; Pan A; Franci C; Hu Y; Chang B; Li W; Duan M; Torneros A; Yu J; Heckrodt TJ; Zhang J; Ding P; Apatira A; Chua J; Brandt R; Pine P; Goff D; Singh R; Payan DG; Hitoshi Y
Cancer Res; 2010 Feb; 70(4):1544-54. PubMed ID: 20145120
[TBL] [Abstract][Full Text] [Related]
16. Inhibiting the GAS6/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma.
Bae CA; Ham IH; Oh HJ; Lee D; Woo J; Son SY; Yoon JH; Lorens JB; Brekken RA; Kim TM; Han SU; Park WS; Hur H
Gastric Cancer; 2020 Sep; 23(5):824-836. PubMed ID: 32239298
[TBL] [Abstract][Full Text] [Related]
17. Dynamic changes in immune cell populations by AXL kinase targeting diminish liver inflammation and fibrosis in experimental MASH.
Grøndal SM; Tutusaus A; Boix L; Reig M; Blø M; Hodneland L; Gausdal G; Jackson A; Garcia de Frutos P; Lorens JB; Morales A; Marí M
Front Immunol; 2024; 15():1400553. PubMed ID: 38817615
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic Inhibition of the Receptor Tyrosine Kinase AXL Improves Sensitivity to Platinum and Taxane in Ovarian Cancer.
Quinn JM; Greenwade MM; Palisoul ML; Opara G; Massad K; Guo L; Zhao P; Beck-Noia H; Hagemann IS; Hagemann AR; McCourt CK; Thaker PH; Powell MA; Mutch DG; Fuh KC
Mol Cancer Ther; 2019 Feb; 18(2):389-398. PubMed ID: 30478151
[TBL] [Abstract][Full Text] [Related]
19. Targeting the TR4 nuclear receptor-mediated lncTASR/AXL signaling with tretinoin increases the sunitinib sensitivity to better suppress the RCC progression.
Shi H; Sun Y; He M; Yang X; Hamada M; Fukunaga T; Zhang X; Chang C
Oncogene; 2020 Jan; 39(3):530-545. PubMed ID: 31501521
[TBL] [Abstract][Full Text] [Related]
20. Targeted inhibition of Axl receptor tyrosine kinase ameliorates anti-GBM-induced lupus-like nephritis.
Zhen Y; Lee IJ; Finkelman FD; Shao WH
J Autoimmun; 2018 Sep; 93():37-44. PubMed ID: 29895432
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
